VERITY
SpecialtyVERITY is a specialty pharmaceutical company focused on Oncology. Key products include TLANDO.
VERITY's Key Drugs
VERITY's core commercial portfolio centers on TLANDO, spanning Oncology — its most strategically important drugs approved in the last 15 years.
VERITY's Recent FDA Approvals
New NDA/BLA approvals for VERITY over the last two years — novel drugs only, excluding generics and label supplements.
VERITY's Therapeutic Areas
VERITY's approved drugs and pipeline span 1 therapeutic area, led by Oncology, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
VERITY's Top Competitors
VERITY's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
VERITY Pipeline Snapshot
VERITY has 1 active clinical program from ClinicalTrials.gov — 1 Phase 3, 0 Phase 2 and 0 Phase 1.
Phase 3 Readout Calendar Pro
1 Phase 3 trial with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • TLANDO leads revenue
- • Drug-level revenue analysis
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2000-06-15
- Latest
- 2025-09-23
- Applications
- 4